Farther Finance Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Farther Finance Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-884	Closed	-$117K	–	4709
2025 Q1	$117K	Buy	884 +724	+453%	+$90.2K	﹤0.01%	1460
2024 Q4	$13.4K	Sell	160 -15	-9%	-$1.23K	﹤0.01%	2258
2024 Q3	$12.8K	Buy	175 +26	+17%	+$1.95K	﹤0.01%	2267
2024 Q2	$10.1K	Buy	149 +57	+62%	+$3.95K	﹤0.01%	2078
2024 Q1	$6.28K	Sell	92 -3	-3%	-$206	﹤0.01%	1961
2023 Q4	$6.8K	Buy	95 +85	+850%	+$4.89K	﹤0.01%	1814
2023 Q3	$521	Sell	10 -26	-72%	-$1.51K	﹤0.01%	2257
2023 Q2	$2.28K	Buy	+36	New	+$2.24K	﹤0.01%	1708
2023 Q1	–	Sell	-3	Closed	-$159	–	2435
2022 Q4	$159	Buy	+3	New	+$150	﹤0.01%	2076

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farther Finance Advisors's ITCI Position: Q2 2025 in Review

Farther Finance Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 884 shares — an estimated $117K sold.

Farther Finance Advisors first reported a position in ITCI in Q4 2022 and held it in 9 quarters. The position peaked at $117K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Farther Finance Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Farther Finance Advisors sold 884 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $117K.
Farther Finance Advisors first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 9 quarters.
Farther Finance Advisors's Intra-Cellular Therapies Inc. position peaked at $117K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Farther Finance Advisors's 13F filing for Q2 2025, filed 11 Jul 2025.